



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/555,949

Art Unit: 1624

Filed: June 6, 2000

Examiner: M. Berch

1st Inventor: T. ISHIKAWA

Allowed:

For: Phosphonocephem Derivatives, Process for the
Preparation of the Same, and Use Thereof

Batch:

Atty. Dkt. No. 2499 USOP

Paper No.: 9

Petition in Accordance with the Requirements of 37 C.F.R. 1.97(d)

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the requirements of 37 C.F.R. 1.97(d):

Accompanying this transmittal is a statement, as specified in 37 C.F.R. 1.97(e).

Applicant hereby petitions for the consideration of the accompanying information
disclosure statement 37 C.F.R. 1.97(d)(2).

An authorization to charge the Deposit Account the petition fee set forth in
§1.17(i) (\$130.00) accompanies this petition.

Respectfully submitted,

Dated: January 22, 2002

(847) 383-3391

(847) 383-3372

Elaine M. Ramesh
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Mark Chao, Ph.D., Reg. No. 37,293
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA

01/28/2002 CCHAU1 00000082 500799 09555949

02 FC:122 130.00 CH



Certificate of Mailing under 37 CFR 1.10

The undersigned hereby certifies that this document, along with any attachments, is being deposited in an envelope addressed to The Commissioner of Patents and Trademarks, with sufficient postage with the United States Postal Service EXPRESS MAIL Post Office to Addressee Service on this date January 22, 2002.

Express Mail Label No. EL 916492466 US

Gail L. Winokur
Printed Name: Gail L. Winokur